文献速递间质性肺疾病

肺康复在特发性肺纤维化中的长期效果:一项随机对照试验

Long-term effect of pulmonary rehabilitation in idiopathic pulmonary fibrosis: a randomised controlled trial.
PubMed 文献 · Thorax · 2023-04-03

肺康复组先进行12周每周两次监测下运动训练,随后40周家庭康复。52周时6分钟步行距离变化两组无显著差异,但耐力时间变化肺康复组显著优于对照组。

要点

  • 接受尼达尼布治疗的IPF患者中,长期肺康复未显著改善52周6分钟步行距离。
  • 肺康复组52周耐力时间改善显著优于对照组。
  • 肺康复方案包括12周监测下训练加40周家庭康复。

核心结论

  • 在接受尼达尼布治疗的IPF患者中,肺康复长期未改善6分钟步行距离,但使耐力时间获得持续改善。

研究设计与样本

  • 开放标签随机对照试验,在19家机构进行,稳定接受尼达尼布治疗的IPF患者按1:1随机分为肺康复组和对照组。
  • 肺康复组接受12周每周两次监测下运动训练,随后40周家庭康复 programme;对照组仅接受常规照护,两组均继续尼达尼布。

主要发现

  • 52周时6分钟步行距离变化:肺康复组-33米(95%CI -65至-1),对照组-53米(95%CI -86至-21),组间差异无统计学意义(平均差21米,95%CI -25至66,p=0.38)。
  • 52周时耐力时间变化:肺康复组64秒(95%CI -42.3至171),对照组-123秒(95%CI -232至-13),组间差异显著(平均差187秒,95%CI 34至153,p=0.019)。

临床怎么用

  • 对于接受尼达尼布治疗的稳定IPF患者,可考虑肺康复以改善运动耐力,但不应期望长期提高6分钟步行距离。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is characterised by worsening dyspnoea and exercise intolerance. RESEARCH QUESTION: Does a long-term pulmonary rehabilitation improve exercise tolerance in patients with IPF treated with standard antifibrotic drugs, which are expected to reduce disease progression? METHODS: This open-label randomised controlled trial was performed at 19 institutions. Stable patients receiving nintedanib were randomised into pulmonary rehabilitation and control groups (1:1). The pulmonary rehabilitation group underwent initial rehabilitation which included twice-weekly sessions of monitored exercise training for 12 weeks, followed by an at-home rehabilitation programme for 40 weeks. The control group received usual care only, without pulmonary rehabilitation. Both groups continued to receive nintedanib. The primary and main secondary outcomes were change in 6 min walking distance (6MWD) and change in endurance time (using cycle ergometry) at week 52. RESULTS: Eighty-eight patients were randomised into pulmonary rehabilitation (n=45) and control (n=43) groups. Changes in 6MWD were -33 m (95% CI -65 to -1) and -53 m (95% CI -86 to -21) in the pulmonary rehabilitation and control groups, respectively, with no statistically significant difference (mean difference, 21 m (95% CI -25 to 66), p=0.38). Changes in endurance time were significantly better in the pulmonary rehabilitation (64 s, 95% CI -42.3 to 171)) than in the control (-123 s (95% CI -232 to -13)) group (mean difference, 187 s (95% CI 34 to 153), p=0.019). INTERPRETATION: Although pulmonary rehabilitation in patients taking nintedanib did not improve 6MWD in the long term, it led to prolonged improvement in endurance time. TRIAL REGISTRATION NUMBER: UMIN000026376.

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Kataoka K, Nishiyama O, Ogura T, et al. Long-term effect of pulmonary rehabilitation in idiopathic pulmonary fibrosis: a randomised controlled trial. Thorax. 2023. PMID: 37012071. doi:10.1136/thorax-2022-219792

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。